MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has MolMed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4HW has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 4HW exceeded the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: 4HW exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is MolMed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is MolMed undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4HW's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4HW's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4HW is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 4HW is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4HW's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4HW is overvalued based on its PB Ratio (7.5x) compared to the DE Biotechs industry average (3.5x).
How is MolMed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MolMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine MolMed's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- MolMed competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has MolMed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4HW is currently unprofitable.
Growing Profit Margin: 4HW is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4HW is unprofitable, but has reduced losses over the past 5 years at a rate of 29.2% per year.
Accelerating Growth: Unable to compare 4HW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4HW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 4HW has a negative Return on Equity (-7.65%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is MolMed's financial position?
Financial Position Analysis
Short Term Liabilities: 4HW's short term assets (€26.6M) exceed its short term liabilities (€15.0M).
Long Term Liabilities: 4HW's short term assets (€26.6M) exceed its long term liabilities (€11.3M).
Debt to Equity History and Analysis
Debt Level: 4HW is debt free.
Reducing Debt: 4HW has no debt compared to 5 years ago when its debt to equity ratio was 22.7%.
Inventory Level: 4HW has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 4HW's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4HW has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4HW has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 11.1% each year.
What is MolMed's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 4HW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 4HW's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4HW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4HW's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4HW's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Riccardo Palmisano 0
Dr. Riccardo Palmisano has been Chief Executive Officer of MolMed S.p.A since December 11, 2015 and has been its Director since October 2015.
CEO Compensation Analysis
Compensation vs Market: Riccardo's total compensation ($USD633.50K) is about average for companies of similar size in the German market ($USD625.18K).
Compensation vs Earnings: Riccardo's compensation has been consistent with company performance over the past year.
|CEO & Director||4.2yrs||€587.00k||no data|
|Founder & Chairman of Scientific Board||0yrs||€470.65k||no data|
|Independent Director||3.8yrs||€30.00k||no data|
|Chairman of the Board||1.4yrs||€85.00k||no data|
|Non-Independent & Non-Executive Director||6.8yrs||€23.00k||no data|
|Lead Independent Director||0yrs||€53.00k||no data|
|Independent Director||6.8yrs||€34.00k||no data|
|Chairman of Statutory Auditor||0yrs||no data||no data|
Experienced Board: 4HW's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.
MolMed S.p.A.'s company bio, employee growth, exchange listings and data sources
- Name: MolMed S.p.A.
- Ticker: 4HW
- Exchange: DB
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €182.600m
- Shares outstanding: 463.45m
- Website: https://www.molmed.com
Number of Employees
- MolMed S.p.A.
- Via Olgettina, 58
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MLM||BIT (Borsa Italiana)||Yes||Common Shares||IT||EUR||Mar 2008|
|0IE3||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Mar 2008|
|4HW||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2008|
|MLMM||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Mar 2008|
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. The company’s pipeline include Zalmoxis (TK), a cell based therapy product, which is in Phase III clinical trial that is used for the treatment of hematological malignancies. Its products pipeline also comprise NGR-hTNF, a biological drug for the treatment of solid tumors, which displays antitumor activity through its specific binding to blood vessels feeding the tumor mass. In addition, the company’s preclinical development product includes CAR-CD44v6, an immuno-gene therapy project for the treatment of various hematological malignancies and epithelial tumors. Further, it conducts cell and gene therapy projects in collaboration with third parties, such as the cGMP production of clinical-grade viral vectors; and manufacturing of patient-specific genetically engineered cells. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 22:04|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.